170 filings
Page 6 of 9
8-K
mr9r3iz
15 Apr 20
Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation April 2020
12:00am
8-K
meq8w0d
16 Mar 20
Departure of Directors or Certain Officers
4:11pm
S-8
jn5m6
2 Mar 20
Registration of securities for employees
4:12pm
8-K
1u02b1l8ey2 b44
28 Feb 20
Departure of Directors or Certain Officers
4:12pm
8-K
vxzsq7
27 Feb 20
Tricida Announces Fourth Quarter and Full-Year 2019 Financial Results
4:11pm
8-K
ruqpamv zo
13 Jan 20
Regulation FD Disclosure
8:02am
8-K
lo7ycs0rbxp3nzjokugp
18 Dec 19
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
12:00am
8-K
39gefz5zl wxm
14 Nov 19
Tricida Announces Third Quarter 2019 Financial Results
4:34pm
8-K
aisa8h
15 Oct 19
Regulation FD Disclosure
8:03am
8-K
0pgwxx4li7usw ca9p
10 Oct 19
Entry into a Material Definitive Agreement
4:25pm
8-K
8slz5f
4 Sep 19
Tricida Announces Submission of New Drug Application for Veverimer for the Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease
9:27am
8-K
1gv5ekyopkuytgf
19 Aug 19
Entry into a Material Definitive Agreement
4:19pm
S-3ASR
r8ou2h09aqgfv2q706
9 Aug 19
Automatic shelf registration
4:21pm
S-8
83koctn7m y55sx3494
9 Aug 19
Registration of securities for employees
4:16pm
8-K
ixx59ue
8 Aug 19
Tricida Announces Second Quarter 2019 Financial Results
4:08pm
8-K
ekz6c6jspy1gelzis0t
25 Jun 19
Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet
8:35am
8-K
9dkb2nqnurc7gxfhqc
31 May 19
Submission of Matters to a Vote of Security Holders
4:39pm